Loading data for GH — first visit, this takes a few seconds.

Alerta

Guardant Health Inc. (GH)

NasdaqGS: GH · Precio en tiempo real · USD

157.21

-2.33 (-1.46%)

Al cierre: Aug 14, 2026, 8:00 PM

157.00

-0.13%

Fuera de horario: 7:58 PM

-1.46% (1D)

No hay datos disponibles

Precio de compra	145.14
Capitalización de mercado	21.1B
Ingresos (TTM)	1.18B
Beneficio neto (TTM)	-453.44M
Beta	1.59
EPS (TTM)	-3.51
Ratio PER (TTM)	n/a
Adelante PE	-349.25
P/B (TTM)	-94.25
P/S (TTM)	17.83
Earnings Date	Oct 28, 2026

Precio de venta	170.08
Volumen	2,450,049
Volumen medio (20D)	2,691,653
Abierto	158.00
Anterior Cerrar	159.54
Rango del día	156.21 - 159.71
Rango de 52 semanas	53.40 - 176.58
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de GH

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; an...

[Leer más]

Industria Diagnostics & Research

Sector Healthcare

IPO Fecha Oct 4, 2018

Empleados 2,490

Bolsa de Valores NasdaqGS

Símbolo bursátil GH

Sitio web https://guardanthealth.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Guardant Health fueron 982.02M, un aumento de 32.88% en comparación con 739.02M del año anterior. Las ganancias fueron -416.28M, una disminución de -4.61%.

Estados financieros

Sorpresa de resultados

Guardant Health ha publicado sus resultados trimestrales en Jul 30, 2026:

Ingresos de $334.98M falla las estimaciones por $0, con 44.33% Crecimiento interanual.

EPS de -0.42 falla las estimaciones por -0.03, con 4.55% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Guardant Health Inc. publique sus resultados el Oct 28, 2026, después del cierre del mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

5 días hace · MarketBeat

Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate

Guardant Health (NASDAQ:GH) highlighted growth across its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference, with co-CEO...

5 días hace · Zacks

Tempus AI's FDA Win Could Unlock Major Reimbursement Growth Ahead

TEM's FDA approval for xT could unlock $85 million in annual revenue from higher pricing, with bigger gains tied to xF.

6 días hace · Zacks

Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High?

TEM's faster growth, rising data demand and reimbursement potential strengthen the bull case, but high valuation and cash burn keep risks in focus.

6 días hace · Motley Fool

Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million

Ian Clark exercised stock options at $50.57 and immediately liquidated the position as the precision oncology company trades near $160 per share.

6 días hace · Simply Wall St.

Guardant Health (GH) Just Gave Investors Something To Think About

Guardant Health (GH) just reported its second quarter 2026 results, with sales of US$334.98 million and a net loss of US$120.14 million, and simultaneously raised its full year 2026 revenue guidance. ...

Página 1 de 2

Guardant Health Inc. (GH)